产品
编 号：F563395
分子式：C29H31ClN8O5
分子量：607.06
分子式：C29H31ClN8O5
分子量：607.06
产品类型
规格
价格
是否有货
结构图
CAS No: 2095432-71-4
产品详情
生物活性：
GSK269962A hydrochloride (GSK 269962 hydrochloride) is a potent ROCK inhibitor with IC50s of 1.6 and 4 nM for recombinant human ROCK1 and ROCK2 respectively. GSK269962A hydrochloride has anti-inflammatory and vasodilatory activities.
体内研究：
GSK269962A is a potent antihypertensive agent. GSK269962A (0.3, 1, and 3 mg/kg; oral gavage) induces a dose-dependent reduction in blood pressure in spontaneously hypertensive rat (SHR). The reduction of blood pressure is acute and substantial.Animal Model:Male Sprague-Dawley rats (350-400g)
Dosage:0.3, 1, and 3 mg/kg
Administration:Oral gavage; 12 hours
Result:Induced a dose-dependent reduction in blood pressure.
体外研究：
GSK269962A has an IC50 of 1.6 nM toward recombinant human ROCK1. GSK269962A exhibits more than 30-fold selectivity against a panel of serine/threonine kinases. GSK269962A induces vasorelaxation in preconstricted rat aorta with an IC50 of 35 nM.
GSK269962A hydrochloride (GSK 269962 hydrochloride) is a potent ROCK inhibitor with IC50s of 1.6 and 4 nM for recombinant human ROCK1 and ROCK2 respectively. GSK269962A hydrochloride has anti-inflammatory and vasodilatory activities.
体内研究：
GSK269962A is a potent antihypertensive agent. GSK269962A (0.3, 1, and 3 mg/kg; oral gavage) induces a dose-dependent reduction in blood pressure in spontaneously hypertensive rat (SHR). The reduction of blood pressure is acute and substantial.Animal Model:Male Sprague-Dawley rats (350-400g)
Dosage:0.3, 1, and 3 mg/kg
Administration:Oral gavage; 12 hours
Result:Induced a dose-dependent reduction in blood pressure.
体外研究：
GSK269962A has an IC50 of 1.6 nM toward recombinant human ROCK1. GSK269962A exhibits more than 30-fold selectivity against a panel of serine/threonine kinases. GSK269962A induces vasorelaxation in preconstricted rat aorta with an IC50 of 35 nM.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备